Peptides and methods of using same
AssigneeSerpin Pharma, LLC
InventorsSoren Mogelsvang, Cohava Gelber
Life of this patent
Estimating the term…
Abstract
We describe peptides and their uses for the treatment of autoimmune, inflammatory and metabolic diseases.
Claims16
A method of treating an inflammatory disease, comprising administering to a human subject affected with the inflammatory disease an oral formulation comprising a peptide selected from the group consisting of:
- (a) a peptide comprising the amino acid sequence X1-Z1-F-N-K-P-F-X2-Z2-X3-Z3-Q (SEQ ID NO:
- 2), wherein
- X1 is V or L;
- X2 is V, L or M;
- X3 is M, I or V;
- Z1 is any amino acid;
- Z2 is a sequence of any two amino acids;
- and
- Z3 is a sequence any five amino acids, and wherein the peptide comprises 37 or fewer amino acids;
- (b) a peptide comprising the amino acid sequence VKFNKPFVFLMIEQNTK (SEQ ID NO:
- 1);
- (c) a peptide consisting essentially of the amino acid sequence X1-Z1-F-N-X2-P-F-X3-Z2-X4-Z3-X5 (SEQ ID NO:
- 3), wherein
- X1 is V or L;
- X2 is K or R;
- X3 is V, L or M;
- X4 is M, I or V;
- X5 is K or Q;
- Z1 is any amino acid;
- Z2 is a sequence of any two amino acids;
- and
- Z3 is a sequence any five amino acids;
- (d) a peptide consisting essentially of the amino acid sequence RFNRPFLR (SEQ ID NO:
- 4).
- (e) a peptide consisting essentially of the amino acid sequence of RRRFNRPFLRRR (SEQ ID NO:
- 8).
- (f) a peptide consisting essentially of the amino acid sequence of VKFNKPFVFLMIEQNTK (SEQ ID NO:
- 1);
- and
- (g) a peptide consisting essentially of the amino acid sequence of FNRPFL (SEQ ID NO:
- 10).
A method of decreasing serum TNF-α levels in a human subject comprising administering to the subject an oral formulation comprising a peptide selected from the group consisting of:
- (a) a peptide comprising the amino acid sequence X1-Z1-F-N-K-P-F-X2-Z2-X3-Z3-Q (SEQ ID NO:
- 2), wherein
- X1 is V or L;
- X2 is V, L or M;
- X3 is M, I or V;
- Z1 is any amino acid;
- Z2 is a sequence of any two amino acids;
- and
- Z3 is a sequence any five amino acids, and wherein the peptide comprises 37 or fewer amino acids;
- (b) a peptide comprising the amino acid sequence VKFNKPFVFLMIEQNTK (SEQ ID NO:
- 1);
- (c) a peptide consisting essentially of the amino acid sequence X1-Z1-F-N-X2-P-F-X3-Z2-X4-Z3-X5 (SEQ ID NO:
- 3), wherein
- X1 is V or L;
- X2 is K or R;
- X3 is V, L or M;
- X4 is M, I or V;
- X5 is K or Q;
- Z1 is any amino acid;
- Z2 is a sequence of any two amino acids;
- and
- Z3 is a sequence any five amino acids;
- (d) a peptide consisting essentially of the amino acid sequence RFNRPFLR (SEQ ID NO:
- 4).
- (e) a peptide consisting essentially of the amino acid sequence of RRRFNRPFLRRR (SEQ ID NO:
- 8).
- (f) a peptide consisting essentially of the amino acid sequence of VKFNKPFVFLMIEQNTK (SEQ ID NO:
- 1);
- and
- (g) a peptide consisting essentially of the amino acid sequence of FNRPFL (SEQ ID NO:
- 10).
A method of improving glycemic control in a subject having hyperglycemia comprising administering to the subject having hyperglycemia an oral formulation comprising a peptide selected from the group consisting of:
- (a) a peptide comprising the amino acid sequence X1-Z1-F-N-K-P-F-X2-Z2-X3-Z3-Q (SEQ ID NO:
- 2), wherein
- X1 is V or L;
- X2 is V, L or M;
- X3 is M, I or V;
- Z1 is any amino acid;
- Z2 is a sequence of any two amino acids;
- and
- Z3 is a sequence any five amino acids, and wherein the peptide comprises 37 or fewer amino acids;
- (b) a peptide comprising the amino acid sequence VKFNKPFVFLMIEQNTK (SEQ ID NO:
- 1);
- (c) a peptide consisting essentially of the amino acid sequence X1-Z1-F-N-X2-P-F-X3-Z2-X4-Z3-X5 (SEQ ID NO:
- 3), wherein
- X1 is V or L;
- X2 is K or R;
- X3 is V, L or M;
- X4 is M, I or V;
- X5 is K or Q;
- Z1 is any amino acid;
- Z2 is a sequence of any two amino acids;
- and
- Z3 is a sequence any five amino acids;
- (d) a peptide consisting essentially of the amino acid sequence RFNRPFLR (SEQ ID NO:
- 4).
- (e) a peptide consisting essentially of the amino acid sequence of RRRFNRPFLRRR (SEQ ID NO:
- 8).
- (f) a peptide consisting essentially of the amino acid sequence of VKFNKPFVFLMIEQNTK (SEQ ID NO:
- 1);
- and
- (g) a peptide consisting essentially of the amino acid sequence of FNRPFL (SEQ ID NO:
- 10).
Dependencies are inferred from the claim text.